⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NGNE News
Neurogene, Inc. Common Stock
Neurogene Inc. Announces Pricing of $125 Million Public Offering
businesswire.com
NGNE
Neurogene Inc. Announces Proposed Public Offering
businesswire.com
NGNE
Form 8-K
sec.gov
NGNE
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
businesswire.com
NGNE
Form 8-K
sec.gov
NGNE
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
businesswire.com
NGNE
Form 8-K
sec.gov
NGNE
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
NGNE
Form 8-K
sec.gov
NGNE
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
businesswire.com
NGNE